ALTHealthcare · BiotechnologyThe 10 Wall Street analysts covering Altimmune, Inc. hold a median 12-month price target of $18 — +514.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 12 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Altimmune, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (75): Sales and profits are climbing, and climbing faster than before.
Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ALT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +514.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 June 2026 | Leerink Partners | Initiates | Outperform | $10 |
| 18 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 May 2026 | Citizens | Maintains | Market Outperform | — |
| 16 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Mar 2026 | B. Riley Securities | Maintains | Buy | — |
| 7 Nov 2025 | Citizens | Maintains | Market Outperform | — |
| 20 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Aug 2025 | B. Riley Securities | Maintains | Buy | — |
| 13 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Aug 2025 | UBS | Maintains | Buy | — |
| 10 July 2025 | JMP Securities | Maintains | Market Outperform | — |
| 27 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Apr 2025 | Citizens Capital Markets | Reiterates | Market Outperform | — |
| 18 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | $12 |
| 14 Mar 2025 | Citizens Capital Markets | Reiterates | Market Outperform | — |
| 3 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Feb 2025 | William Blair | Initiates | Market Perform | — |
| 5 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALT appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 87% of US stocks
Cheaper than 1% of US stocks
Cheaper than 60% of US stocks
Cheaper than 75% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 23% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Altimmune, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Altimmune, Inc. released the transcript of its Q2 2026 earnings call, as republished by Seeking Alpha. The item presents the official earnings-call discussion for that quarter.
Why it matters — The earnings-call transcript offers ALT watchers the company's own commentary on its Q2 2026 results and outlook.
Altimmune has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for MASH and is advancing plans for later-stage development in alcohol use disorder.
Why it matters — The start of a Phase III trial and expansion into a new indication mark key clinical milestones for Altimmune's lead drug candidate.
Altimmune announced its second-quarter 2026 financial results and business update, reporting $519 million in cash, cash equivalents and investments as of June 30, 2026. The company initiated the global PERFORMA Phase 3 trial in MASH, reported positive topline data from the RECLAIM Phase 2 trial in AUD, and completed patient enrollment in the RESTORE Phase 2 trial in ALD.
Why it matters — The update notes progress across several clinical programs, including initiation of a Phase 3 MASH trial and positive Phase 2 AUD data, alongside a cash position as of mid-2026.
Altimmune announced it will report its second quarter 2026 financial results and provide a business update on August 12, 2026. The company is a late clinical-stage biopharmaceutical firm developing pemvidutide for serious liver diseases.
Why it matters — This announcement provides a date for shareholders to expect the company's next quarterly financial report and any updates on its lead drug candidate, pemvidutide.
Altimmune has initiated the PERFORMA Phase 3 global registrational trial of pemvidutide for patients with MASH, designed to evaluate the drug's effect on fibrosis improvement, MASH resolution, and clinical outcomes.
Why it matters — This marks a major clinical milestone for Altimmune as pemvidutide advances to the final stage of pivotal testing needed for potential regulatory approval in MASH.
The 10 Wall Street analysts covering Altimmune, Inc. have a median 12-month price target of $18, with estimates ranging from $11 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Altimmune, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Altimmune, Inc. 24 out of 100 across roughly 4,600 US stocks as at 12 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Aug 2026, Altimmune, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (75 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +514.3% from the last close, and Ticker Nerd's factor model ranks Altimmune, Inc. 24 out of 100 as at 12 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Altimmune, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $28 over the next 12 months.
Altimmune, Inc. returned -19.1% over the 12 months to 12 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based therapeutics for obesity, metabolic diseases, and liver diseases.
The most recent item we track (Seeking Alpha, 12 Aug 2026): "Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript". Altimmune, Inc. released the transcript of its Q2 2026 earnings call, as republished by Seeking Alpha. The item presents the official earnings-call discussion for that quarter.
Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based therapeutics for obesity, metabolic diseases, and liver diseases. Its lead product candidate, pemvidutide, is a novel GLP-1/glucagon dual receptor agonist designed to address obesity and metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH). Pemvidutide activates GLP-1 to suppress appetite and glucagon to increase energy expenditure and promote hepatic fat metabolism, mimicking effects of diet and exercise. The company is advancing pemvidutide in clinical trials for these indications, leveraging its differentiated profile for potential broader applications. Additionally, Altimmune develops HepTcell, an immunotherapeutic aimed at achieving a functional cure for chronic hepatitis B through Phase II trials conducted internationally. Operating wholly owned subsidiaries supports its global development efforts in peptide therapeutics targeting unmet needs in metabolic and liver health sectors. Founded in 1997 and headquartered in Gaithersburg, Maryland, Altimmune focuses on next-generation treatments in these critical therapeutic areas.
CEO Mr. Jerome Benedict Durso · 57 employees · United States · https://altimmune.com